What is povorcitinib and how does it work for vitiligo?

Povorcitinib is an oral, once-daily JAK1 inhibitor made by Incyte. It blocks JAK1-dependent signaling — including the interferon-gamma/CXCL10 pathway believed to drive the immune attack on melanocytes in vitiligo. By interrupting that signal, the ongoing destruction of pigment-producing cells slows, giving surviving melanocytes room to repigment affected skin.

Is povorcitinib approved for vitiligo yet?

No. Incyte announced that its Phase 3 trial met its primary and key secondary endpoints in May 2026. The company has indicated it plans to file for FDA approval in the first half of 2027. Until that filing is reviewed and approved, povorcitinib is not available for vitiligo outside of clinical trials.

How is povorcitinib different from Opzelura and upadacitinib?

Povorcitinib is an oral tablet, unlike Opzelura, which is a topical cream applied twice daily to specific patches. Compared to upadacitinib (Rinvoq), another oral JAK inhibitor in the vitiligo pipeline, povorcitinib is a JAK1/TYK2 inhibitor rather than JAK1-selective — the practical difference for patients is still being worked out, since both target the same broad inflammatory pathway.

Can I get povorcitinib for vitiligo right now?

Not through a standard prescription. Povorcitinib is already approved for hidradenitis suppurativa in some markets, which means off-label prescribing may be technically possible in the US, but most dermatologists will wait for vitiligo-specific approval and dosing data before prescribing it for that use. Ask your dermatologist whether any local clinical trials are enrolling.

Povorcitinib for Vitiligo: The Newest Oral Pill in the Pipeline

If you have been tracking the oral JAK inhibitor pipeline for vitiligo, you already know the shortlist: upadacitinib, ritlecitinib, and now povorcitinib. Incyte announced in May 2026 that its Phase 3 trial in vitiligo met its primary and key secondary endpoints — which puts a third oral pill on a path toward approval, alongside the two already further along.

Here is what povorcitinib is, what the data shows so far, and — because this is the question I get asked most about pipeline drugs — what it actually means for someone with vitiligo today.

What povorcitinib is

Povorcitinib (Incyte’s development code INCB54707) is an oral, once-daily JAK1/TYK2 inhibitor. Like the other oral JAK inhibitors being studied for vitiligo, it works by blocking JAK-STAT signaling — specifically the interferon-gamma and CXCL10 pathway that drives the autoimmune attack on melanocytes, the cells responsible for producing skin pigment.

Povorcitinib is not a new molecule invented for vitiligo. It has been in development for several inflammatory conditions, and it already has an approval in some markets for hidradenitis suppurativa, a chronic inflammatory skin condition. Incyte is now extending its development into vitiligo, following the same playbook AbbVie used with upadacitinib — a drug already approved for other conditions, tested in a new indication where the same inflammatory pathway is relevant.

Where it sits in the pipeline

It helps to see this next to the other oral options in development:

	Povorcitinib	Upadacitinib (Rinvoq)	Ritlecitinib (LITFULO)
Maker	Incyte	AbbVie	Pfizer
Target	JAK1 / TYK2	JAK1-selective	JAK3 / TEC family
Form	Oral, once daily	Oral, once daily	Oral, once daily
Vitiligo trial status	Phase 3 endpoints met, May 2026	Phase 3 complete; FDA/EMA filed Feb 2026	Phase 3 (Tranquillo) complete, early 2026
Expected filing	H1 2027	Decision expected late 2026–early 2027	Decision pending
Already approved for	Hidradenitis suppurativa (some markets)	RA, psoriatic arthritis, atopic dermatitis, and others	Alopecia areata

The pattern across all three is the same: a JAK inhibitor already used for another inflammatory condition, repurposed for vitiligo because the underlying immune pathway overlaps. None of the three is approved for vitiligo yet. Upadacitinib is furthest along in the regulatory process; povorcitinib is the newest entrant with a filing timeline roughly a year behind it.

What the Phase 3 data actually showed

Incyte’s announcement in May 2026 confirmed the trial met its primary endpoint (typically measured as facial or total VASI improvement — the standard vitiligo severity scoring used across this drug class) and key secondary endpoints. As of this writing, Incyte has not published the full topline numbers — response rates, timing to first response, or the magnitude of improvement — in a form intended for a general audience. Full data is expected at a future dermatology conference or in a peer-reviewed publication, which is the normal path other JAK inhibitors in this space have followed.

I would treat “met its endpoints” as a meaningful positive signal, not as proof of how well it will actually work for a given patient. That distinction matters. A trial can be statistically positive while still showing a response rate that requires realistic expectations — the Phase 3 tofacitinib-vs-tacrolimus data, for comparison, showed a 47% meaningful-response rate in the tofacitinib arm, which was positive but far from universal.

What this means for patients now

Practically, nothing changes yet. Povorcitinib is not prescribable for vitiligo. If your dermatologist mentions it, the honest framing is: this is a drug to know about, not a drug to ask for yet.

A few things worth doing while the pipeline plays out:

Ask about clinical trial enrollment. If Incyte or a research site near you is running an open-label extension or expanded trial, that may be the only route to access before approval.
Don’t wait on treatment you can start now. If you have active, spreading vitiligo, delaying evidence-based care (NB-UVB, tacrolimus, Opzelura where appropriate) to “wait for the pill” is usually the wrong call — untreated active disease can spread further in the meantime.
Watch the filing timeline, not the headline. “Met Phase 3 endpoints” is a milestone, not an approval. The realistic timeline to prescription is H1 2027 filing, followed by the FDA’s standard review period — likely into 2028 before it reaches pharmacies, assuming approval.

How it might fit once approved

If povorcitinib is approved, it will likely slot in similarly to upadacitinib and ritlecitinib: an option for patients with widespread, non-segmental vitiligo where topical treatment alone is impractical, or for patients who have not responded adequately to Opzelura and NB-UVB. Whether povorcitinib ends up preferred over upadacitinib or ritlecitinib for a given patient will come down to head-to-head data (which does not yet exist), side-effect profile, and insurance coverage — much the same set of factors that currently drive the choice between tacrolimus and Opzelura for topical treatment.

All oral JAK inhibitors, povorcitinib included, are expected to carry the same class-level FDA boxed warning covering serious infections, cardiovascular events, blood clots, cancer, and mortality — based on data in older, higher-risk populations from unrelated conditions. That warning will be part of the conversation with your dermatologist regardless of which oral JAK inhibitor eventually reaches you.

My take

Three oral JAK inhibitors moving through Phase 3 for the same condition, within about a year of each other, tells you something real: this mechanism works well enough that multiple companies are betting on it. That is good news for anyone whose vitiligo has not responded well to topical treatment alone. It also means the field is about to get more crowded and more confusing before it gets simpler — expect a wave of “which oral JAK inhibitor is right for me” conversations once the first one or two are approved.

For now, povorcitinib is a name worth knowing, not a prescription worth waiting for.

Also on VitiligoTreatmentInfo.com

Upadacitinib (Rinvoq) for vitiligo — furthest along in the regulatory process
Ritlecitinib (LITFULO) for vitiligo — the other oral JAK inhibitor with completed Phase 3 data
Opzelura complete patient guide — the current FDA-approved topical standard
Vitiligo treatment options compared